New guidance outlines use of first immunotherapy for children newly diagnosed with type 1 diabetes

The FDA has expanded approval of the immunotherapy drug teplizumab to children and adolescents aged 8 to 17 newly diagnosed with stage 3 type 1 diabetes, allowing it to slow the destruction of insulin-producing cells and preserve the body's own insulin production. New clinical guidance from the University of Colorado Anschutz team helps care providers integrate this disease-modifying treatment into paediatric diabetes care.

This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it between 11 Nov 2026 and 12 Nov 2026.